Abstract
Objective
To evaluate the role of phenobarbitone in the management of unconjugated hyperbilirubinemia during first two weeks of life in preterm neonates.
Design
Meta-analysis.
Methods
A study was eligible for inclusion in the meta-analysis if it randomized preterm neonates into control and treatment groups. Standard search strategy of the Cochrane Neonatal Review Group was used. For categorical and continuous data the odds ratio (OR) and weighted mean difference (WMD) were calculated, respectively. 95% confidence intervals were used and a fixed effects model was assumed for the meta-analysis.
Main outcome measures
Peak serum bilirubin, duration of phototherapy, need of phototherapy and exchange transfusion, neurodevelopmental outcome and adverse effects.
Results
A total of 19 potentially relevant studies were identified. Of these, 3 studies (497 neonates) were included in the meta-analysis. Peak serum bilirubin was significantly lower in phenobarbitone group (mean difference: −1.78 mg/dL, 95% CI: −2.29 to −1.27). Duration of phototherapy was shorter (mean difference: −14.75 h, 95% CI: −26.67 to −2.83). Need of phototherapy (OR: 0.33, 95% CI: 0.13 to 0.81) and exchange transfusion (OR: 0.30, 95% CI: 0.14 to 0.64) were also reduced in phenobarbitone group.
Conclusion
Phenobarbitone reduces peak serum bilirubin, duration and need of phototherapy and need of exchange transfusion in preterm very low birthweight neonates. Further studies are warranted to evaluate adverse effects and neurodevelopmental outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hack M, Horbar JD, Malloy MH, Tyson JE, Wright E, Wright L. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. Pediatrics 1991; 87: 587–597.
Singhal PK, Singh M, Paul VK, Deorari AK, Ghorpade MG. Spectrum of neonatal hyperbilirubinemia: an analysis of 454 cases. Indian Pediatr 1992; 29: 319–325.
Narang A, Gathwala G, Kumar P. Neonatal jaundice: an analysis of 551 cases. Indian Pediatr 1997; 34: 429–432.
Narang A, Kumar P, Kumar R. Neonatal jaundice in very low birth weight babies. Indian J Pediatr 2001; 68: 307–309.
Amin SB. Clinical assessment of bilirubin-induced neurotoxicity in premature infants. Semin Perinatol 2004; 28: 340–347.
Benders MJ, van Bel F, van de Bor M. The effect of phototherapy on renal blood flow velocity in preterm infants. Biol Neonate 1998; 73: 228–234.
Rosenfeld W, Sadhev S, Brunot V, Jhaveri R, Zabaleta I, Evans HE. Phototherapy effect on the incidence of patent ductus arteriosus in premature infants: prevention with chest shielding. Pediatrics 1986; 78: 10–14.
Cochrane Neonatal Review Group. Guidelines for Reviewers and Editors. Available from: http://neonatal.cochrane.org. Accessed March 30, 2008.
Moher D, Cook DJ, Eastwood S, Otkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896–1900.
Ruth V, Virkola K, Paetau R, Raivio KO. Early high-dose phenobarbital treatment for prevention of hypoxic-ischemic brain damage in very low birth weight infants. J Pediatr 1988; 112: 81–86.
Kumar R, Narang A, Kumar P, Garewal G. Phenobarbitone prophylaxis for neonatal jaundice in babies with birth weight 1000–1499 grams. Indian Pediatr 2002; 39: 945–951.
Carswell F, Kerr MM, Dunsmore IR. Sequential trial of effect of phenobarbitone on serum bilirubin of preterm infants. Arch Dis Child 1972; 47: 621–625.
Stern L, Khanna NN, Levy G, Yaffe SJ. Effect of phenobarbital on hyperbilirubinemia and glucuronide formation in newborns. Am J Dis Child 1970; 120: 26–31.
Anwar M, Valdivieso J, Hiatt IM, Hegyi T. The course of hyperbilirubinemia in the very low birth weight infant treated with phenobarbital. J Perinatol 1987; 7: 145–148.
Epstein MF, Kuban K, Skoutelli H, Meltzer K, Brown E, Krishnamoorthy K, et al. Reduced incidence of hyperbilirubinemia in low birthweight babies receiving phenobarbital. Pediatr Res 1985; 19: 340A.
Vest M, Signer E, Weisser K, Olafsson A. A double blind study of the effect of phenobarbitone on neonatal hyperbilirubinaemia and frequency of exchange transfusion. Acta Paediatr Scand 1970; 59: 681–684.
Trolle D. Decrease of total serum-bilirubin concentration in newborn infants after phenobarbitone treatment. Lancet 1968; 2: 705–708.
Ramboer C, Thompson RP, Williams R. Controlled trials of phenobarbitone therapy of neonatal jaundice. Lancet 1969; 1: 966–968.
Yeung CY, Field CE. Phenobarbitone therapy in neonatal hyperbilirubinaemia. Lancet 1969; 2: 135–139.
Wallin A, Jalling B, Boreus LO. Plasma concentrations of phenobarbital in the neonate during prophylaxis for neonatal hyperbilirubinemia. J Pediatr 1974; 85:392–397.
Whitelaw A, Odd D. Postnatal phenobarbital for the prevention of intraventricular hemorrhage in preterm infants. Cochrane Database Syst Rev 2007: CD001691.
Donn SM, Roloff DW, Goldstein GW. Prevention of intraventricular haemorrhage in preterm infants by phenobarbitone. A controlled trial. Lancet 1981; 2: 215–217.
Bedard MP, Shankaran S, Slovis TL, Pantoja A, Dayal B, Poland RL. Effect of prophylactic phenobarbital on intraventricular hemorrhage in high-risk infants. Pediatrics 1984; 73: 435–439.
Morgan ME, Massey RF, Cooke RW. Does phenobarbitone prevent periventricular hemorrhage in very low-birth-weight babies?: A controlled trial. Pediatrics 1982; 70: 186–189.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chawla, D., Parmar, V. Phenobarbitone for prevention and treatment of unconjugated hyperbilirubinemia in preterm neonates: A Systematic Review and Meta-analysis . Indian Pediatr 47, 401–407 (2010). https://doi.org/10.1007/s13312-010-0075-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-010-0075-5